• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

485.39 -11.11 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,430,186
Open 498.15
Bid (Size) 483.10 (40)
Ask (Size) 487.29 (40)
Prev. Close 496.50
Today's Range 484.33 - 498.91
52wk Range 362.50 - 533.67
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is This Biotech Stock a Buy Near Its 52-Week High? ↗
Today 17:20 EDT
It's been a volatile year for the company, but don't let that scare you away. 
Via The Motley Fool
News headline image
Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
Today 15:22 EDT
It is getting acquired by a larger firm in the sector. 
Via The Motley Fool
Topics Bonds

Performance

YTD
+7.4%
+7.4%
1 Month
+8.9%
+8.9%
3 Month
+8.6%
+8.6%
6 Month
+3.3%
+3.3%
1 Year
+1.3%
+1.3%

More News

Read More
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
Today 13:20 EDT
Via The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
June 23, 2026
Via Chartmill
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
Today 4:25 EDT
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Momentum Stock to Research Further and 2 Facing Headwinds
July 09, 2026
Via StockStory
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
July 08, 2026
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
July 08, 2026
Via The Motley Fool
News headline image
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
July 08, 2026
Via The Motley Fool
News headline image
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
July 07, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
July 07, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Cash-Heavy Stocks with Promising Prospects
July 07, 2026
Via StockStory
Which S&P500 stocks are showing activity after the closing bell on Monday? ↗
July 06, 2026
Via Chartmill
News headline image
Vertex to Acquire Crinetics Pharmaceuticals
July 06, 2026
From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via Business Wire
News headline image
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗
July 06, 2026
Via The Motley Fool
News headline image
While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗
July 05, 2026
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
July 03, 2026
Via The Motley Fool
News headline image
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
July 01, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
July 01, 2026
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
June 29, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
June 29, 2026
Via Benzinga
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 27, 2026
Via The Motley Fool
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
June 23, 2026
Via MarketBeat
Topics ETFs
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
June 22, 2026
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
June 22, 2026
Via StockStory

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 485.39
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 07/10/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 125.92B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 126B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap